STOCK TITAN

Inogen to Present at 41st Annual J.P. Morgan Healthcare Conference

Inogen, Inc. (NASDAQ: INGN), a medical technology company specializing in respiratory products, has announced its participation in the 41st Annual J.P.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Nabil Shabshab, President and Chief Executive Officer, is scheduled to present on Wednesday, January 11, 2023, at 10:30 a.m. Pacific Time.

A live webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. The Company primarily develops, manufactures, and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Agnes Lee
ir@inogen.net

Source: Inogen, Inc.

Keep reading